The prognosis for nearly three-quarters of elderly patients on intensive chemotherapy for acute myeloid leukemia (AML) is poor, with a median survival of less than six months, according to a study published online in Blood, the journal of the American Society of Hematology. AML is the most common form of acute leukemia among adults and… Continue reading